Mallinckrodt Plc, a major manufacturer of generic opioids, is backing an investor’s request it disclose its lobbying spending and plans to issue a report, according to a shareholder coalition pressing drug companies to improve oversight in light of the opioid epidemic and confirmed by the company’s proxy statement released Wednesday. The Staines-upon-Thames, England-based company told members of Investors for Opioid Accountability, who together manage $3.4 trillion in assets, it would recommend stockholders vote in favor of the group’s lobbying disclosure proposal, said co-leader Donna Meyer and Katie McCloskey, director of social responsibility for IOA member United Church Funds, lead filer of the request. “The company is making an important step,” McCloskey said. “They’re willing to be on the record with it, and I think that’s something to be applauded for. We’re just going to monitor it and see how they do.” A … [Read more...] about Opioid maker Mallinckrodt to support lobbying disclosure
Investors for opioid accountability
By Bloomberg | March 8, 2019 at 10:39 am By Polly Mosendz, Brandon Kochkod and Alexandra Stratton | Bloomberg State pension funds have historically taken stands against controversial industries, like firearms and tobacco, sometimes divesting their investments to push companies to act. But in the opioid crisis, which has generated hundreds of lawsuits seeking to hold manufacturers and distributors accountable, the funds have mostly stayed on the sideline so far. Some of the biggest ones, including New York and California pension funds, hold investments in Endo International, the largest maker of opioids after privately held Purdue Pharma LP. Even in West Virginia, which has been racked by opioid-related deaths, the state pension fund has a $1.8 million equity stake in Endo. “West Virginia is literally and metaphorically ground zero for both the opioid epidemic and litigation,” said Charles Webb, an attorney at Webb Law Centre, which represents towns that brought … [Read more...] about California and other state pensions fought guns and tobacco. Why aren’t they divesting from opioids?
Peter Whoriskey and Dan Keating, The Washington Post Published 7:05 pm PST, Sunday, November 25, 2018 Pottsviile, Penn., is the home one of HCR ManorCare's facility. Pottsviile, Penn., is the home one of HCR ManorCare's facility. Photo: Washington Post Photo By Michael S. Williamson Photo: Washington Post Photo By Michael S. Williamson Image 1 of / 3 Caption Close Image 1 of 3 Pottsviile, Penn., is the home one of HCR ManorCare's facility. Pottsviile, Penn., is the home one of HCR ManorCare's facility. Photo: Washington Post Photo By Michael S. Williamson Distress detailed at nursing homes that went bankrupt after investors made millions 1 / 3 Back to Gallery POTTSVILLE, Pa. - To … [Read more...] about Distress detailed at nursing homes that went bankrupt after investors made millions
The First FDA-Approved Treatment for These Rare, Life-Threatening Neuroendocrine Cancers in Patients Aged 12 and Older Company to Host Conference Call Tomorrow at 8:00 AM ET NEW YORK, July 30, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZEDRA (iobenguane I 131) 555 MBq/mL injection for intravenous use. AZEDRA, a radiotherapeutic, is indicated for the treatment of adult and pediatric patients 12 years and older with iobenguane scan positive, unresectable, locally advanced or metastatic pheochromocytoma or paraganglioma who require systemic anticancer therapy. AZEDRA is the first and only approved therapy for this indication. AZEDRA can cause serious side effects including risk from radiation exposure, bone marrow problems and other cancers (myelosuppression and secondary malignancies), thyroid problems (hypothyroidism), elevations in … [Read more...] about Progenics Pharmaceuticals Announces FDA Approval for AZEDRA® (iobenguane I 131) to Treat Unresectable, Locally Advanced or Metastatic Pheochromocytoma or Paraganglioma
Every day, the opioid epidemic claims 115 American lives, while communities across the country are awash in prescription drugs that fuel the crisis. But while the human toll of this tragedy has become all too clear, the fight to hold accountable those responsible for exacerbating the crisis continues. Nowhere will this be more apparent or urgent than at San Francisco-based McKesson’s annual meeting Wednesday. At the crossroads of our nation’s drug pipeline are America’s three largest drug distributors — McKesson, AmerisourceBergen and Cardinal Health — which have played an outsized role in fueling the flow of opioids into our communities. McKesson, the largest of the “Big Three,” supplied 5 million doses of prescription opioids over two years to a town in West Virginia with a population of 400, according to a letter released by a congressional committee investigating opioid abuse. That is more than 12,000 doses for every man, woman and child. … [Read more...] about Investors: Hold McKesson accountable for exacerbating opioid crisis